DK3237621T3 - Varianter af human alpha-galactosidase - Google Patents

Varianter af human alpha-galactosidase Download PDF

Info

Publication number
DK3237621T3
DK3237621T3 DK15874075.3T DK15874075T DK3237621T3 DK 3237621 T3 DK3237621 T3 DK 3237621T3 DK 15874075 T DK15874075 T DK 15874075T DK 3237621 T3 DK3237621 T3 DK 3237621T3
Authority
DK
Denmark
Prior art keywords
galactosidase
variants
human alpha
alpha
human
Prior art date
Application number
DK15874075.3T
Other languages
English (en)
Other versions
DK3237621T5 (da
Inventor
Nicholas J Agard
Mathew G Miller
Xiyun Zhang
Gjalt W Huisman
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of DK3237621T3 publication Critical patent/DK3237621T3/da
Application granted granted Critical
Publication of DK3237621T5 publication Critical patent/DK3237621T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15874075.3T 2014-12-22 2015-12-02 Varianter af human alpha-galactosidase DK3237621T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095313P 2014-12-22 2014-12-22
US201562216452P 2015-09-10 2015-09-10
PCT/US2015/063329 WO2016105889A1 (en) 2014-12-22 2015-12-02 Human alpha-galactosidase variants

Publications (2)

Publication Number Publication Date
DK3237621T3 true DK3237621T3 (da) 2023-06-19
DK3237621T5 DK3237621T5 (da) 2024-10-14

Family

ID=56151383

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15874075.3T DK3237621T5 (da) 2014-12-22 2015-12-02 Varianter af human alpha-galactosidase

Country Status (20)

Country Link
US (6) US20170360900A1 (da)
EP (2) EP4234699A1 (da)
JP (5) JP6650943B2 (da)
KR (2) KR102702200B1 (da)
AU (2) AU2015370125B2 (da)
BR (1) BR112017013300A2 (da)
CA (1) CA2970638A1 (da)
CY (1) CY1126231T1 (da)
DK (1) DK3237621T5 (da)
ES (1) ES2944889T3 (da)
FI (1) FI3237621T3 (da)
HR (1) HRP20230468T1 (da)
HU (1) HUE062016T2 (da)
IL (1) IL252479B (da)
LT (1) LT3237621T (da)
PL (1) PL3237621T3 (da)
PT (1) PT3237621T (da)
RS (1) RS64574B1 (da)
SI (1) SI3237621T1 (da)
WO (1) WO2016105889A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170360900A1 (en) 2014-12-22 2017-12-21 Codexis, Inc. Human alpha-galactosidase variants
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
KR20180088919A (ko) * 2015-12-24 2018-08-07 옥시레인 유케이 리미티드 인간 알파-n-아세틸갈락토사미니다아제 폴리펩티드
US12239693B2 (en) 2018-04-27 2025-03-04 The Medical College Of Wisconsin, Inc. Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders
WO2020047282A1 (en) 2018-08-29 2020-03-05 University Of Copenhagen Lysosomal enzymes modified by cell based glycoengineering
MX2021007552A (es) * 2018-12-20 2021-08-11 Codexis Inc Variantes de alfa-galactosidasa humana.
MX2022002473A (es) 2019-08-30 2022-08-02 Codexis Inc Variantes de lipasa modificadas geneticamente.
WO2021055801A1 (en) * 2019-09-18 2021-03-25 The Medical College Of Wisconsin, Inc. Improved alpha-galactosidase protein for enzyme replacement therapy (ert) and methods of use
PE20221266A1 (es) * 2019-12-20 2022-08-16 Codexis Inc Variantes de alfa-glucosidasa acida disenadas por ingenieria
IL295818A (en) * 2020-02-28 2022-10-01 Codexis Inc Human alpha-galactosidase variants

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US753653A (en) 1903-09-14 1904-03-01 American Car & Foundry Co Hopper-bottom car.
US6846968B1 (en) 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
ATE294871T1 (de) 1994-06-30 2005-05-15 Novozymes Biotech Inc Nicht-toxisches, nicht-toxigenes, nicht- pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
PT1538202E (pt) 1996-09-13 2014-04-22 Shire Human Genetic Therapies Produção de alga-galactosidase a humana
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
AU743305C (en) 1997-01-17 2006-03-30 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6066626A (en) 1997-10-29 2000-05-23 Genzyme Corporation Compositions and method for treating lysosomal storage disease
AU746786B2 (en) 1997-12-08 2002-05-02 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
WO2000042560A2 (en) 1999-01-19 2000-07-20 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
CA2362737A1 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Recombination of insertion modified nucleic acids
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
AU4964101A (en) 2000-03-30 2001-10-15 Maxygen Inc In silico cross-over site selection
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
WO2003075129A2 (en) 2002-03-01 2003-09-12 Maxygen, Inc. Methods, systems, and software for identifying functional bio-molecules
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US7620500B2 (en) 2002-03-09 2009-11-17 Maxygen, Inc. Optimization of crossover points for directed evolution
BR122017016940B8 (pt) 2002-04-25 2021-07-27 Transkaryotic Therapies Inc método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8504498B2 (en) 2008-02-12 2013-08-06 Codexis, Inc. Method of generating an optimized, diverse population of variants
EP2250594B1 (en) 2008-02-12 2017-04-19 Codexis, Inc. Method of generating an optimized, diverse population of variants
EP2285958B1 (en) 2008-06-13 2016-03-09 Codexis, Inc. Method of synthesizing polynucleotide variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US9194011B2 (en) * 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US8876066B1 (en) 2009-12-17 2014-11-04 Progressive Fastening, Inc. Hanger with bolt closures
EP3025728B1 (en) 2010-02-04 2018-08-08 BioMarin Pharmaceutical Inc. Method for purifying prokaryotic phenylalanine ammonia-lyase variants
DK2865751T3 (da) * 2010-03-02 2017-01-09 Protalix Ltd Stabiliseret alpha-galactosidase og anvendelser deraf
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
HUE042817T2 (hu) 2011-06-28 2019-07-29 Codexis Inc Fehérjevariánsok elõállítása régiókeveréssel
JP5431428B2 (ja) 2011-09-02 2014-03-05 京楽産業．株式会社 遊技機
WO2013138339A1 (en) 2012-03-15 2013-09-19 Codexis, Inc. Gene shuffling methods
DK2839001T3 (da) 2012-04-18 2017-12-11 Vib Vzw Midler og fremgangsmåder til frembringelse af forbedrede proteiner
RU2664695C2 (ru) 2013-01-31 2018-08-21 Кодексис, Инк. Способы, системы и программное обеспечение для идентификации биомолекул с помощью моделей мультипликативной формы
EP3049979B1 (en) 2013-09-27 2020-01-01 Codexis, Inc. Structure based predictive modeling
HUE039618T2 (hu) 2013-09-27 2019-01-28 Codexis Inc Enzimvariánsok automatizált szûrése
US9909113B2 (en) 2014-06-12 2018-03-06 Research Foundation Of The City University Of New York Purification of recombinant alpha galactosidase A
US20170360900A1 (en) 2014-12-22 2017-12-21 Codexis, Inc. Human alpha-galactosidase variants
US20170051267A1 (en) 2015-08-20 2017-02-23 Research Foundation Of The City University Of New York Novel alpha-galactosidase a derivatives
EP3896164A1 (en) 2016-05-18 2021-10-20 ModernaTX, Inc. Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease
TW201829770A (zh) 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
BR112020012346A2 (pt) 2017-12-22 2020-11-24 Hanmi Pharm. Co., Ltd. proteína de fusão enzimática terapêutica tendo uma nova estrutura e uso da mesma
MX2021007552A (es) 2018-12-20 2021-08-11 Codexis Inc Variantes de alfa-galactosidasa humana.
JP2021021820A (ja) 2019-07-26 2021-02-18 富士ゼロックス株式会社 画像形成装置及びプログラム
WO2021026447A1 (en) 2019-08-07 2021-02-11 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
IL295818A (en) 2020-02-28 2022-10-01 Codexis Inc Human alpha-galactosidase variants
CA3264923A1 (en) 2022-08-25 2024-02-29 Takeda Pharmaceutical Company Limited COMPOSITION INTENDED FOR USE IN THE TREATMENT OF FABRY'S DISEASE

Also Published As

Publication number Publication date
KR102702200B1 (ko) 2024-09-02
JP2018500907A (ja) 2018-01-18
SI3237621T1 (sl) 2023-11-30
JP2021003129A (ja) 2021-01-14
IL252479B (en) 2021-03-25
AU2022202939B2 (en) 2025-03-06
EP3237621A4 (en) 2018-12-05
EP4234699A1 (en) 2023-08-30
EP3237621B1 (en) 2023-04-19
WO2016105889A1 (en) 2016-06-30
HUE062016T2 (hu) 2023-09-28
KR20170093976A (ko) 2017-08-16
US20170360900A1 (en) 2017-12-21
CA2970638A1 (en) 2016-06-30
IL252479A0 (en) 2017-07-31
US12257291B2 (en) 2025-03-25
US20200360489A1 (en) 2020-11-19
AU2015370125A1 (en) 2017-06-22
NZ732171A (en) 2021-01-29
JP7785315B2 (ja) 2025-12-15
JP2024150549A (ja) 2024-10-23
HRP20230468T1 (hr) 2023-11-10
AU2022202939A1 (en) 2022-05-26
US20250041388A1 (en) 2025-02-06
RS64574B1 (sr) 2023-10-31
US20210244804A1 (en) 2021-08-12
US10973888B2 (en) 2021-04-13
PT3237621T (pt) 2023-07-20
AU2015370125B2 (en) 2022-02-03
BR112017013300A2 (pt) 2018-02-27
FI3237621T3 (fi) 2023-06-01
US20200360490A1 (en) 2020-11-19
ES2944889T3 (es) 2023-06-26
EP3237621A1 (en) 2017-11-01
US12263207B2 (en) 2025-04-01
PL3237621T3 (pl) 2023-10-30
CY1126231T1 (el) 2026-02-25
US11278600B2 (en) 2022-03-22
JP2019076110A (ja) 2019-05-23
US20200405826A1 (en) 2020-12-31
JP7675443B2 (ja) 2025-05-13
KR102438885B1 (ko) 2022-09-01
LT3237621T (lt) 2023-09-25
KR20220123342A (ko) 2022-09-06
US11497798B2 (en) 2022-11-15
DK3237621T5 (da) 2024-10-14
JP2022097653A (ja) 2022-06-30
JP6650943B2 (ja) 2020-02-19

Similar Documents

Publication Publication Date Title
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3235465T3 (da) Implantat
PL3417725T3 (pl) Fajka wodna
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3331876T3 (da) Modulators of ror-gamma
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3237621T5 (da) Varianter af human alpha-galactosidase
DK3132009T3 (da) Fremgangsmåde
DK3283210T3 (da) Fremgangsmåde
DK3307267T3 (da) Behandling af multipel sklerose
DK3418273T3 (da) Derivater af flavagliner
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3151814T3 (da) Behandling af en hudlæsion
DK3113773T3 (da) Krystallinske former af grapiprant
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
IL254825A0 (en) Methods of treatment with taselisib
IL254502A0 (en) Solid forms of menaquinols
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme
FR3024647B1 (fr) Transat de puericulture
FR3022129B1 (fr) Baignoire de puericulture
DK3200783T3 (da) Behandling af erytromelalgi